Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Background Cladribine provides immunomodulation through selective targeting of lymphocyte
subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet …

Multiple sclerosis (MS) is a common, complex neurological disease. The precise aetiology
of MS is not yet known, although epidemiological data indicate that both genetic and …

Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Background Multiple sclerosis (MS) is a leading cause of disability in young adults.
Susceptibility to MS is determined by environmental exposure on the background of genetic risk …

Background Natalizumab is the first α 4 integrin antagonist in a new class of selective
adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in …

Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective
properties in preclinical experiments and to result in significant reductions in disease …

Multiple sclerosis ( MS ) is the commonest non‐traumatic disabling disease to affect young
adults. The incidence of MS is increasing worldwide, together with the socioeconomic impact …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …

Objective: To evaluate the association between diagnosis of Parkinson disease (PD) and
risk factors or early symptoms amenable to population‐based screening. Methods: A …